Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.
Ontology highlight
SUBMITTER: Ohanian M
PROVIDER: S-EPMC11840760 | biostudies-literature | 2018 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA